|
1
|
Ghose A, Bolina A, Mahajan I, Raza SA,
Clarke M, Pal A, Sanchez E, Rallis KS and Boussios S: Hereditary
ovarian cancer: towards a cost-effective prevention strategy. Int J
Environ Res Public Health. 19:120572022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ
and Brown ML: Projections of the cost of cancer care in the United
States: 2010–2020. J Natl Cancer Inst. 103:117–128. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duska LR and Kohn EC: The new
classifications of ovarian, fallopian tube, and primary peritoneal
cancer and their clinical implications. Ann Oncol. 28 (Suppl
8):viii8–viii12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlidis N, Rassy E, Vermorken JB, Assi T,
Kattan J, Boussios S and Smith-Gagen J: The outcome of patients
with serous papillary peritoneal cancer, fallopian tube cancer, and
epithelial ovarian cancer by treatment eras: 27 Years data from the
SEER registry. Cancer Epidemiol. 75:1020452021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aliyuda F, Moschetta M, Ghose A, Sofia
Rallis K, Sheriff M, Sanchez E, Rassy E and Boussios S: Advances in
ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug
Targets. 23:433–446. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghose A, Gullapalli SVN, Chohan N, Bolina
A, Moschetta M, Rassy E and Boussios S: Applications of proteomics
in ovarian cancer: Dawn of a new era. Proteomes. 10:162022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Otsuka I: Cutaneous metastases in ovarian
cancer. Cancers (Basel). 11:12922019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Z, Xu M, Sakandar A, Du X, He H, He
W, Li D and Wen Q: Successful treatment of a patient with brain
metastasis from ovarian cancer with BRCA wild type using niraparib:
A case report and review of the literature. Front Oncol.
12:8731982022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Otsuka I and Matsuura T: Skin metastases
in epithelial ovarian and fallopian tube carcinoma. Medicine
(Baltimore). 96:e77982017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim MK, Kim SH, Lee YY, Choi CH, Kim TJ,
Lee JW, Lee JH, Bae DS and Kim BG: Metastatic skin lesions on lower
extremities in a patient with recurrent serous papillary ovarian
carcinoma: A case report and literature review. Cancer Res Treat.
44:142–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sehra D, Singhal S, Bhatla N, Meena J,
Singh A, Kumari R and Sharma S: 2022-RA-1602-ESGO Cutaneous
metastasis in epithelial ovarian cancer: Experience from a tertiary
care cancer institute. Int J Gynecol Cancer. 32 (Suppl
2):A352–A353. 2022.
|
|
12
|
Kanyilmaz G, Aktan M, Koc M and Findik S:
Cutaneous metastases of the synchronous primary endometrial and
bilateral ovarian cancer: An infrequent presentation and literature
review. Case Rep Oncol Med. 2016:45686532016.PubMed/NCBI
|
|
13
|
Tharakaram S: Metastases to the skin. Int
J Dermatol. 27:240–242. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang TT, Lampert EJ, Coots C and Lee JM:
Targeting the PI3K pathway and DNA damage response as a therapeutic
strategy in ovarian cancer. Cancer Treat Rev. 86:1020212020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dienstmann R, Rodon J, Serra V and
Tabernero J: Picking the point of inhibition: A comparative review
of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brownstein MH and Helwig EB: Patterns of
cutaneous metastasis. Arch Dermatol. 105:862–868. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cormio G, Capotorto M, Di Vagno G,
Cazzolla A, Carriero C and Selvaggi L: Skin metastases in ovarian
carcinoma: A report of nine cases and a review of the literature.
Gynecol Oncol. 90:682–685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Charalampidis C, Lampaki S, Zarogoulidis
P, Lazaridis G, Mpaka S, Kosmidis C, Tsakiridis K, Kioumis I,
Pavlidis P, Karapantzos I, et al: Fine-needle aspiration of skin
metastasis in ovarian cancer-report of two cases and review of the
literature. Ann Transl Med. 4:4472016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Demirci S, Yavas F, Ozsaran Z, Ozsaran A,
Dikmen Y, Zekioglu O, Karabulut B and Aras AB: Palliative
radiotherapy for the skin metastasis of ovarian cancer: A case
report and review of the literature. Med Oncol. 27:628–631. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Achimaş-Cadariu P, Vlad C, Fetica B, Zgaia
A and Cainap C: Unusual skin metastasis in a patient with recurrent
micropapillary serous ovarian carcinoma-a case report and review of
the literature. Clujul Med. 88:237–240. 2015.PubMed/NCBI
|
|
21
|
Vitner D, Amit A, Kerner H, Mayer E and
Lowenstein L: Cutaneous metastases from epithelial ovarian cancer.
Harefuah. 150:441–442. 4912011.(In Hebrew). PubMed/NCBI
|
|
22
|
Haughney RV, Slade RJ and Brain AN: An
isolated abdominal wall metastasis of ovarian carcinoma ten years
after primary surgery. Eur J Gynaecol Oncol. 22:102–103.
2001.PubMed/NCBI
|
|
23
|
Coco D and Leanza S: Cutaneous metastasis
in ovarian cancer: Case report and literature review. Maedica
(Bucur). 15:552–555. 2020.PubMed/NCBI
|
|
24
|
Zylberberg B, Dormont D, Madelenat P and
Daraï E: Relapse after more than 20 years of follow-up for
epithelial ovarian carcinoma. Obstet Gynecol. 103:1082–1084. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oh SR, Park JW, Kwon HY and Rha SH:
BRCA1-mutated ovarian cancer with skin metastasis: A case report.
Obstet Gynecol Sci. 60:477–480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shah S, Cheung A, Kutka M, Sheriff M and
Boussios S: Epithelial ovarian cancer: Providing evidence of
predisposition genes. Int J Environ Res Public Health. 19:81132022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang S, Royer R, Li S, McLaughlin JR,
Rosen B, Risch HA, Fan I, Bradley L, Shaw PA and Narod SA:
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected
patients with invasive ovarian cancer. Gynecol Oncol. 121:353–357.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Revythis A, Limbu A, Mikropoulos C, Ghose
A, Sanchez E, Sheriff M and Boussios S: Recent insights into PARP
and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int
J Environ Res Public Health. 19:85772022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stewart RA, Pilié PG and Yap TA:
Development of PARP and immune-checkpoint inhibitor combinations.
Cancer Res. 78:6717–6725. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Chen Y, Li F, Bao L and Liu W:
Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian
cancer cells progression synergistically via suppressing
epithelial-mesenchymal transition. Front Immunol. 10:8672019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T,
Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, et al: PARP inhibition
elicits STING-dependent antitumor immunity in brca1-deficient
ovarian cancer. Cell Rep. 25:2972–2980.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Palfi A, Toth A, Hanto K, Deres P,
Szabados E, Szereday Z, Kulcsar G, Kalai T, Hideg K, Gallyas F Jr,
et al: PARP inhibition prevents postinfarction myocardial
remodeling and heart failure via the protein kinase C/glycogen
synthase kinase-3beta pathway. J Mol Cell Cardiol. 41:149–159.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nero C, Ciccarone F, Pietragalla A,
Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G and Lorusso
D: Ovarian cancer treatments strategy: Focus on PARP inhibitors and
immune check point inhibitors. Cancers (Basel). 13:12982021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Traiman P, de Luca LA and Bacchi CE: An
extremely large, cauliflower-type, cutaneous metastasis of ovarian
cancer associated with good prognosis. Gynecol Oncol. 53:239–241.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Karpate SJ, Samal SL and Jain SM:
Recurrent ovarian malignancy presenting as cutaneous metastasis.
Indian J Dermatol. 54:380–381. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hastings V, McEachron J and Kanis MJ:
Cutaneous metastasis of PD-L1 positive ovarian carcinoma. Gynecol
Oncol Rep. 33:1006072020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
António AM, Alves JV, Goulão J and Bártolo
E: Ovarian carcinoma presenting as cutaneous nasal metastasis. An
Bras Dermatol. 91 (5 suppl 1):S101–S104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stien S, Loget J, Soibinet P, Durlach A,
Fleury C and Viguier M: Ovarian cancer revealed by mammary skin
metastases and cutaneous lymphangitis. Ann Dermatol Venereol.
146:663–665. 2019.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schwartz RA: Cutaneous metastatic disease.
J Am Acad Dermatol. 33:161–186. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brownstein MH and Helwig EB: Metastatic
tumors of the skin. Cancer. 29:1298–1307. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Prat J, D'Angelo E and Espinosa I: Ovarian
carcinomas: At least five different diseases with distinct
histological features and molecular genetics. Hum Pathol. 80:11–27.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thomakos N, Diakosavvas M, Machairiotis N,
Fasoulakis Z, Zarogoulidis P and Rodolakis A: Rare distant
metastatic disease of ovarian and peritoneal carcinomatosis: A
review of the literature. Cancers (Basel). 11:10442019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Erickson BK, Conner MG and Landen CN Jr:
The role of the fallopian tube in the origin of ovarian cancer. Am
J Obstet Gynecol. 209:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paolucci V, Schaeff B, Schneider M and
Gutt C: Tumor seeding following laparoscopy: International survey.
World J Surg. 23:989–997. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leary A, Cowan R, Chi D, Kehoe S and
Nankivell M: Primary surgery or neoadjuvant chemotherapy in
advanced ovarian cancer: The debate continues…. Am Soc Clin Oncol
Educ Book. 35:153–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Moschetta M, Boussios S, Rassy E,
Samartzis EP, Funingana G and Uccello M: Neoadjuvant treatment for
newly diagnosed advanced ovarian cancer: Where do we stand and
where are we going? Ann Transl Med. 8:17102020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wiechert AC, Garrett LA, Lin G and Goodman
A: Management of a skin metastasis in a patient with advanced
ovarian cancer. Gynecol Oncol Case Rep. 2:124–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bottoni C, Scambia G, Fagotti A and
Petrillo M: The safety of bevazicumab for the treatment of ovarian
cancer. Expert Opin Drug Saf. 17:1107–1113. 2018. View Article : Google Scholar : PubMed/NCBI
|
